ArticleTranslational cancer research2026
Palmitoylation-related gene signature for immune subtyping, prognostic stratification, and immunotherapy guidance in hepatocellular carcinoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) remains a significant global health burden, with high mortality rates due to late diagnosis and limited therapeutic options. Palmitoylation, a reversible post-translational modification, has emerged as a critical regulator of cancer progression, yet its role in HCC remains underexplored. This study aims to investigate the diagnostic and prognostic value of palmitoylation-related genes (acyltransferase and acylthioesterase) in HCC, focusing on their potential as biomarkers and therapeutic targets. Methods: Transcriptomic and clinicopathologic data from 377 HCC patients in The Cancer Genome Atlas (TCGA) cohort and 231 HCC patients in the International Cancer Genome Consortium (ICGC) cohort were analyzed. Differential gene expression analysis identified palmitoylation-related genes significantly associated with HCC. Univariate Cox and least absolute shrinkage and selection operator (LASSO) regression analyses were employed to construct a predictive model based on these genes. The model's performance was validated using the ICGC dataset. Functional enrichment, immune microenvironment analysis, and machine learning approaches were further applied to explore the biological roles and clinical relevance of the identified genes. Results: We identified 20 differentially expressed palmitoylation-related genes in HCC, of which eight were significantly associated with overall survival (OS). A predictive model incorporating ZDHHC18, ZDHHC23, and PPT1 was developed, stratifying patients into high- and low-risk groups with distinct survival outcomes. The model demonstrated robust predictive performance, with area under the curve (AUC) values of 0.700 (1 year), 0.653 (2 years), and 0.634 (3 years) in the TCGA cohort, and 0.773 (1 year), 0.705 (2 years), and 0.703 (3 years) in the ICGC cohort. Functional enrichment analysis revealed significant differences in immune-related pathways between risk groups, highlighting the model's potential in guiding immunotherapy strategies. Conclusions: This study establishes a novel predictive model based on palmitoylation-related genes, offering valuable insights into HCC prognosis and potential therapeutic targets. The model's ability to stratify patients by risk and its association with immune microenvironment characteristics underscores its clinical relevance, paving the way for personalized treatment strategies in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.